アプリケーター、塗布器

WordNet

a device for applying a substance (同)applier
an applicator for applying flux (as in soldering)

PrepTutorEJDIC

(特に)薬を塗る用具(へら,綿棒など)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/01/27 07:33:16」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 子宮内避妊器具：挿入および除去 intrauterine contraceptive device insertion and removal
2. エトノゲストレル避妊インプラント etonogestrel contraceptive implant
3. 肺腫瘍の画像ガイド下焼灼術 image guided ablation of lung tumors
4. 女性の腹腔鏡下避妊手術 laparoscopic female sterilization
5. フィブリンシーラント fibrin sealants

English Journal

Sucralfate paste enema: a new method of topical treatment for haemorrhagic radiation proctitis.

McElvanna K1, Wilson A, Irwin T.Author information 1Department of Colorectal Surgery, Royal Victoria Hospital, Belfast, UK.AbstractAIM: Rectal sucralfate has been reported to deliver clinical improvement in haemorrhagic radiation proctitis, but patients with active proctitis find the enema suspension difficult to retain thus reducing compliance and effectiveness. We describe a novel method of rectal administration via a low-volume sucralfate paste and report its results in a series of 23 patients.
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.Colorectal Dis.2014 Apr;16(4):281-4. doi: 10.1111/codi.12507.
AIM: Rectal sucralfate has been reported to deliver clinical improvement in haemorrhagic radiation proctitis, but patients with active proctitis find the enema suspension difficult to retain thus reducing compliance and effectiveness. We describe a novel method of rectal administration via a low-vol
PMID 24299100

Metastatic malignant melanoma: computed tomography-guided 125I seed implantation treatment.

Shi F1, Zhang X, Wu K, Gao F, Ding Y, Maharjan R, Zhang R, Zhang F, Li C.Author information 1Department of Medical Imaging & Interventional Radiology, Cancer Center and State Key Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, People's Republic of China.AbstractThe aim of this study is to evaluate the therapeutic efficacy of computed tomography (CT)-guided interstitial iodine-125 (I) seed implantation for metastatic malignant melanoma treatment. From November 2008 to May 2011, 24 patients with metastatic malignant melanoma who had undergone surgery for excision of primary lesions and repeated chemotherapy underwent CT-guided I seed implantation. Their clinical situations, biochemical indicators, MRIs, and CTs were observed. The follow-up time ranged from 5 to 24 months (mean 19.6 months). The local control rates of metastatic malignant melanoma after surgery excision for primary lesion after 2, 6, 12, and 24 months were 86.8, 78.6, 62.1, and 55.0%, respectively. One patient died of liver failure 5 months after brachytherapy and another died of a metastatic brain tumor 8 months after brachytherapy. Two patients died of lung dysfunction from pulmonary metastases 15 months after brachytherapy. All other patients survived throughout the follow-up period. The 2-year survival rate was 83.3%. During the procedure, one patient presented with minimal bleeding from the applicator route and another presented with pneumothorax with 20% pulmonary compression, which improved after intraprocedure suctioning. Four patients had low-grade fever on day 3. Three showed mild decreases in their white blood cell counts. CT-guided I seed implantation is a safe, feasible, and promising approach to the treatment of patients with metastatic malignant melanoma after surgery excision for primary lesions and repeated chemotherapy, but large-scale randomized clinical trials should be conducted before the technique can be used routinely.
Melanoma research.Melanoma Res.2014 Apr;24(2):137-43. doi: 10.1097/CMR.0000000000000028.
The aim of this study is to evaluate the therapeutic efficacy of computed tomography (CT)-guided interstitial iodine-125 (I) seed implantation for metastatic malignant melanoma treatment. From November 2008 to May 2011, 24 patients with metastatic malignant melanoma who had undergone surgery for exc
PMID 24589507

Adherence in the CAPRISA 004 Tenofovir Gel Microbicide Trial.

Mansoor LE1, Abdool Karim Q, Yende-Zuma N, Macqueen KM, Baxter C, Madlala BT, Grobler A, Abdool Karim SS.Author information 1Centre for the AIDS Programme of Research in South Africa, 2nd Floor, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Private Bag X7, Congella, 4013, South Africa, mansoor@ukzn.ac.za.AbstractHigh adherence is key to microbicide effectiveness. Here we provide a description of adherence interventions and the adherence rates achieved in the CAPRISA 004 Tenofovir gel trial. Adherence support for the before-and-after dosing strategy (BAT 24) was provided at enrolment and at each monthly study visit. This initially comprised individual counselling and was replaced midway by a structured theory-based adherence support program (ASP) based on motivational interviewing. The 889 women were followed for an average of 18 months and attended a total of 17,031 monthly visits. On average women reported five sex acts and returned 5.9 empty applicators per month. The adherence rate based on applicator count in relation to all reported sex acts was 72.2 % compared to the 82.0 % self-reported adherence during the last sex act. Adherence support activities, which achieve levels of adherence similar to or better than those achieved by the CAPRISA 004 ASP, will be critical to the success of future microbicide trials.
AIDS and behavior.AIDS Behav.2014 Mar 19. [Epub ahead of print]
High adherence is key to microbicide effectiveness. Here we provide a description of adherence interventions and the adherence rates achieved in the CAPRISA 004 Tenofovir gel trial. Adherence support for the before-and-after dosing strategy (BAT 24) was provided at enrolment and at each monthly stud
PMID 24643315